The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique
Open Access
- 11 February 2003
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 55 (2) , 182-190
- https://doi.org/10.1046/j.1365-2125.2003.01722.x
Abstract
Aims To investigate whether the drug–drug interaction between fexofenadine and ketoconazole is localized to efflux transport proteins of the small intestine, and to determine and classify the effective jejunal permeability (Peff) of fexofenadine according to the Biopharmaceutics Classification System (BCS).Methods Two separate jejunal perfusion experiments were performed using the Loc‐I‐Gut® technique in eight healthy volunteers. During treatment 1 (T1), we investigated the acute effect of ketoconazole on the Peff and plasma pharmacokinetics of fexofenadine. In treatment 2 (T2) we examined the effect of oral pretreatment with ketoconazole (200 mg daily for 5 days) on the same absorption parameters. Each experiment was divided into two periods of 100 min and the jejunal segment was perfused with 93 µm fexofenadine during both periods. In period 2 of each treatment, fexofenadine was coadministered with 94 µm ketoconazole. The concentrations of fexofenadine in intestinal perfusate and plasma were measured by liquid chromatography with mass detection.Results During T1, the mean (± s.d.) Peff of fexofenadine was low according to the BCS (0.11 ± 0.11 and 0.04 ± 0.13·10−4 cm s−1 in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference −0.37, 0.51). After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0.29 ± 0.47 and 0.22 ± 0.31·10−4 cm s−1 in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference −0.62, 0.27 for T1 0–100 min vs T2 0–100 min; −0.54, 0.34 for T1 0–100 min vs T2 100–200 min). Fexofenadine plasma AUC from 0–100 mg showed no significant difference after pretreatment with ketoconazole (55 ± 101 and 51 ± 33 µg ml−1 min−1 respectively; 95% CI on the difference −108, 115). Total plasma AUC (0–720 min) was 318 ± 426 and 426 ± 232 ng ml−1 min in T1 and T2, respectively (95% CI on the difference −622, 405).Conclusions No significant effect of acute coadministration or pretreatment with ketoconazole on the in vivo intestinal absorption of fexofenadine was detected in this study.Keywords
This publication has 37 references indexed in Scilit:
- MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadineBritish Journal of Clinical Pharmacology, 2002
- Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensusBritish Journal of Clinical Pharmacology, 2001
- Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidineBritish Journal of Clinical Pharmacology, 2000
- Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) FamilyBiochemical and Biophysical Research Communications, 2000
- FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on LabelingThe Journal of Clinical Pharmacology, 1999
- The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humansPublished by Wiley ,1999
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis ApproachJournal of Medicinal Chemistry, 1998
- Human Intestinal PermeabilityJournal of Pharmaceutical Sciences, 1998
- In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic InteractionThe Journal of Clinical Pharmacology, 1994